You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

Details for Patent: 11,166,947

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,166,947 protect, and when does it expire?

Patent 11,166,947 protects COTEMPLA XR-ODT and is included in one NDA.

This patent has six patent family members in five countries.

Summary for Patent: 11,166,947

Title:	Effective dosing of a child for the treatment of ADHD with methylphenidate
Abstract:	The present invention generally relates to treating attention-deficit disorders (e.g., ADHD) by providing an effective amount of an ADHD-effective agent to a patient in need thereof (e.g., a child).
Inventor(s):	Tengler; Mark (Colleyville, TX), Teuscher; Nathan (Trophy Club, TX)
Assignee:	Neos Therapeutics, LP (Grand Prairie, TX)
Application Number:	16/346,850
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 11,166,947

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS	⤷ Sign Up
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-002	Jun 19, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS	⤷ Sign Up
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-003	Jun 19, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,166,947

PCT Information
PCT Filed	October 31, 2017	PCT Application Number:	PCT/US2017/059256
PCT Publication Date:	May 11, 2018	PCT Publication Number:	WO2018/085256

International Family Members for US Patent 11,166,947

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017353921	⤷ Sign Up
European Patent Office	3585439	⤷ Sign Up
Japan	2020504763	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.